and inflammation, have been identified (Biteker, Kayatas, Duman, Turkmen, & Bozkurt, 2014; Dalzell, Jackson, & Gardner, 2011; Fett & McTiernan, 2011) . Clinical course range from complete recovery of left ventricular (LV) function to progressive heart failure, thromboembolic complications, life-threatening arrhythmias, and even cardiac death (Goland et al., 2015; Karaye & Henein, 2013; Nishimoto et al., 2012) . Therefore, the ability to determine early predictors of prognosis in women diagnosed with PPCM is of utmost importance in risk stratification, using reasonable management strategies, preventing complications and improving outcome. Predictors of adverse outcomes are inconsistently defined in several studies and include lower baseline LV EF, higher baseline LV end-diastolic diameter, older age, and black race (Fett, Christie, Carraway, & Murphy, 2005; Goland et al., 2009 ).
Upright T wave in lead aVR (TaVR) on a routine 12-lead electrocardiogram (ECG), as a marker of repolarization abnormality, suggested to be a powerful, independent prognostic predictor of cardiovascular (CV) mortality in the general population (Anttila et al., 2011; Badheka et al., 2013; Tan, Engel, Myers, Sandri, & Froelicher, 2008) as well as in some cardiovascular diseases (Ayhan et al., 2013; Okuda et al., 2011; Torigoe et al., 2012) . However, evidence on the prognostic role of positive TaVR in PPCM patients has been lacking. Therefore, we aimed to evaluate the prognostic role of upright TaVR in predicting arrhythmic events, persistent LV systolic dysfunction, and cardiovascular mortality in patients with PPCM.
| MATERIAL AND ME THODS

| Study population
We conducted a retrospective analysis of 82 consecutive patients Peripartum cardiomyopathy was accepted as an occurrence of unexplained cardiomyopathy with LVEF <45% presenting toward the end of pregnancy or soon after delivery in a previously healthy woman (Sliwa et al., 2010) . All patients were at least 18 years of age.
Women with any previous congenital or significant organic valvular heart disease, coronary heart disease (≥50% luminal stenosis in at least one major coronary arteries and their branches), a history of cardiomyopathy, complete left bundle branch block, right ventricular pacing, or without interpretable admission ECG were excluded from this study.
The follow-up period was commenced with the first admission and ended with the occurrence of death, arrhythmic event or device therapy or the last visit. The duration of follow-up was at least 12 months after diagnosis for all participants. All patients had undergone echocardiographic measurements at the time of diagnosis and the last followup visit. Recovery of LV systolic function was defined as the presence of LVEF ˃45%. The implantable cardioverter defibrillator (ICD) devices were routinely interrogated whenever symptomatic events relevant to ventricular tachycardia or ICD shock delivery happened and also at 6-month intervals. Monitorized intracardiac ECG recordings were evaluated regarding cardiac arrhythmias. All patients were given standard treatment for heart failure including beta blockers, angiotensin-converting enzyme inhibitors (or angiotensin-receptor blocker), digitalis.
None of the women received bromocriptine.
| Study endpoints
The primary endpoint was defined as composite cardiac events that included cardiac death, arrhythmic event (a malignant cardiac arrhythmia [sustained VT and/or VF and/or appropriate ICD shock]), or persistent LV systolic dysfunction. Cardiac mortality, arrhythmic event, persistent LV systolic dysfunction, and a combination of death and arrhythmic event were evaluated, respectively, as secondary endpoints.
| Electrocardiographic evaluation
A standard 12-lead surface electrocardiogram (25 mm/s and 10 mm = 1 mV) in the supine position was obtained from all patients on first admission. Conventional ECG parameters including heart rate, PR interval, QRS duration, QT duration, bundle branch block, QRS axis, abnormal Q waves, T-wave inversion, left ventricular hypertrophy (Sokolow & Lyon voltage amplitude criteria SV 1 + RV 5 or V 6 ) were calculated. The QTc was calculated using Bazett's formula.
Presence of abnormal Q wave was defined as a Q wave with more than 25% of the QRS complex depth in at least two contiguous leads.
In addition to these conventional parameters, the T-wave amplitude in lead aVR was analyzed. The T-wave amplitude was described as the first deflection after the QRS complex and/or the maximum deviation from the PR isoelectric line. A positive T wave was described as a wave with a positive deflection ˃0 mV. Negative TaVR was defined as TaVR ≤0 mm. The T-wave amplitudes in lead aVR were measured manually. The amplitude of positive T wave when present was determined in each ECG. The 12-lead electrocardiogram of each patient was assessed by two independent cardiologists blinded to the patients' clinical outcomes.
| Echocardiographic evaluation
Standard 2-dimensional and Doppler echocardiographic measurements were performed in all women by experienced echocardiographers using 2.5 to 4-MHz transducers (Vivid 7; GE Medical System, Milwaukee, WI, USA). LV EF was measured using the modified Simpson rule. 
| Statistical analysis
| RE SULTS
From April 2009 to May 2017, 94 patients were identified with the diagnosis of PPCM. A total of 82 patients with diagnosis of PPCM were included in the analysis after excluding 12 patients due to complete left bundle branch block in seven patients, ventricular pacing in two patients, or missing clinical and follow-up data in three patients. Baseline clinical, demographical, ECG, and echocardiographic characteristics of the study population comparing patients with positive T waves in aVR and patients with negative T waves were described in Table 1 . The mean age of the study population at diagnosis was 29.1 ± 6.3 years. Positive T wave in lead aVR was present in 30 patients (36.6%). Negative T wave and flat T wave were present in 47 patients (57.3%) and five patients (6.1%), respectively. The prevalence of smoking, hypertension, diabetes mellitus, hyperlipidemia, positive family history of dilated cardiomyopathy, chronic obstructive pulmonary disease (COPD), coronary artery disease (CAD), stroke, and atrial fibrillation were similar in two groups.
NYHA functional class 3-4 on admission was significantly higher in patients with positive TaVR (70.0% vs. 19.2%, p < 0.001; Table 1 ).
With regard to echocardiographic parameters, the LV EDD and LV ESD were greater in patients with positive T wave in lead aVR, whereas the LVEF was smaller in patients with positive TaVR. With regard to ECG parameters, the mean heart rate, PR, QRS, QTc interval, T-wave inversion in inferolateral leads and complete RBBB were similar in two groups. The prevalences of abnormal Q waves were significantly higher in patients with a positive T wave in lead aVR than in those without it. Follow-up data and clinical outcomes were presented in Table 2 . During a follow-up period of median 67.0 (12.0-192.0) months, primary endpoint developed in 48 of 82 subjects (58.5%). Among these subjects, cardiac death was observed as a secondary endpoint in six subjects (7.3%; sudden death in four, death for progressive heart failure in two), arrhythmic event was observed as a secondary endpoint in eight subjects (9.8%), and persistent LV systolic dysfunction was observed as a secondary endpoint in 47 subjects (57.3%). During the study period, one left ventricular assist device implantation, one heart transplantation, and six embolic events (four among nonrecovery group and two among recovery group) occurred in patients. In addition, electrocardiographic parameters regarding occurrence of death and presence of death or arrhythmic events in patients with positive T wave in lead aVR were compared in Table 3 .
A Kaplan-Meier analysis showed a significantly lower primary composite event-free survival rate in patients with positive TaVR (log-rank, p = 0.001; Figure 1 ). Total arrhythmic events occurred more frequently in the positive TaVR group (log-rank, p = 0.017).
Persistent LV systolic dysfunction developed more frequently in the positive TaVR than in those with negative T waves in lead aVR (log-rank, p = 0.001) Also, patients with positive TaVR had a higher cardiac death rate compared with patients without positive TaVR (log-rank, p = 0.001; Figure 2 ).
Univariate logistic regression analyses showed that initial LV EF, LV EDD, duration of QTc interval, positive T waves in lead aVR were significantly associated with the primary endpoint (for all, p < 0.05; 
TA B L E 2 Comparison of clinical outcomes according to the presence of positive T wave in lead aVR
confounding factors (odds ratio 6.21; 95% confidence interval 1.45-26.51; p = 0.014; Table 4 ).
The ROC curve analysis explored the discriminatory capability of T-wave positivity in lead aVR for primary composite endpoint.
Area under the curve was 1.000 (p < 0.001). Using a cut-off level of 0.25 mV, T-wave amplitude in lead aVR predicted primary endpoint with a sensitivity of 100% and specificity of 100% (Figure 3) . In addition, the specificity and positive predictive value to predict primary endpoint were 91.2% and 90%, respectively
| D ISCUSS I ON
The main findings of present study were as follows: F I G U R E 1 Kaplan-Meier curve analysis of the composite primary endpoint in lead aVR predicted primary endpoint with a sensitivity of 100%
and specificity of 100%.
Peripartum cardiomyopathy is a unique type of cardiomyopathy with a significant likelihood of myocardial recovery. Previous studies have revealed that many women with PPCM recover LV function partially or fully; however, markedly reduced cardiac function and failure to recover can be associated with adverse cardiac events including lethal ventricular tachyarrhythmias, thromboembolic complications, and even death (Goland et al., 2009; Misumida et al., 2016) . The attempts to discover clinical markers for poor prognosis in women with PPCM have resulted in determination of a number of parameters with moderate and inconsistent relations with cardiac outcomes. Several investigators have demonstrated a correlation between a lower LV EF at the time of diagnosis and a worse outcome in these women (Fett et al., 2005; Sliwa et al., 2010) . Also, some studies have showed a relation between an increased LV EDD on the initial echocardiogram and persistent LV systolic dysfunction (Chapa et al., 2005) .
However, other investigators have found no correlation between the admission LVEF-LV EDD and survival (Amos, Jaber, & Russell, 2006; Forster et al., 2008) . The lack of ability to predict outcomes accurately makes clinical decision-making challenging as a PPCM patient with initially low EF may recover; therefore, the use of advanced therapies such as ICDs, left ventricular assist devices, or heart transplantation, may have been risky if used too late.
From this perspective, novel approaches to risk stratification require establishments of new, widely available risk markers such as those identified from the surface 12-lead electrocardiogram. To our knowledge, there is a paucity of ECG data in PPCM, and scarce data on its use in the risk stratification of PPCM. In recent years, the presence of positive T wave in lead aVR on a routine 12-lead ECG has become a marker of repolarization abnormality. It has been shown that positive TaVR is associated with increased mortality and arrhythmic events both in the general population (Anttila et al., 2011; Badheka et al., 2013) as well as in some clinical settings such as renal failure on hemodialysis, acute coronary syndromes, or myocardial infarction and ischemic or nonischemic cardiomyopathies (Sato, Hayashi, Joki, & Fujimoto, 2017; Separham et al., 2018; Tanaka et al., 2017) . In a study with 7,928 participants enrolled in the National Health and Nutrition Examination Survey (NHANES) III, Badheka et al. (2013) showed that the amplitude of T wave in lead aVR was a significant and independent predictor of cardiovascular adverse outcomes.
In addition, adding this factor to Framingham risk score could improve model's discriminator capability on intermediate-risk subjects. The underlying mechanism for development of positive T wave in lead aVR in patients with PPCM is unclear. Lead aVR is the augmented unipolar right limb lead and may be considered as looking into the cavity of the heart and opposes the direction of the main cardiac vector. Under normal circumstances, all upright deflections on the ECG will be negative in this lead (Rautaharju et al., 2009a) . When repolarization of injured myocardial cells is delayed compared with that of normal regions, the direction of the T-wave vector alters toward the injured myocardial regions. Given the position of the aVR lead, the presence of injured myocardium in the apical, inferior, and lower lateral regions of the left ventricle would lead to a normally negative T wave inverted and manifested as a positive T wave in lead aVR (Rautaharju et al., 2009b) . It has been assumed that any myocardial disease process that would cause T-wave inversions in the inferolateral leads would be accompanied by a positive T wave in lead aVR (George, Arumugham, & Figueredo, 2010) . However, according to our study results, only aVR revealed an independent and significant association with both primary and secondary endpoints in terms of logistic regression analysis. Therefore, we hypothesized that positive T waves in lead aVR were not just mirror images of negative T waves in inferolateral leads, but also a more sensitive marker of myocardial injury and presumably widespread pathological remodeling in cases of PPCM. These findings should encourage prospective outcome studies accompanied by imaging studies to explain the underlying pathophysiology.
We also studied other ECG findings; however, only positive T wave in lead aVR showed a strong and significant association with primary endpoint by multivariate logistic regression analysis even after adjustment for LV EF and LV EDD, which are well-known but inconsistent traditional predictors of CV outcomes of PPCM patients. The Kaplan-Meier curves began to separate early and then continued to stay separate until the end of follow-up for CV death, arrhythmic events, and persistent LV dysfunction. Our findings supported the findings of previous studies and extended the literatural knowledge about the association of positive T wave in lead aVR with adverse cardiac outcomes. Positive TaVR, as a simple, widely available, and unique ECG marker, seems to be a new predictor of worsening heart failure, arrhythmic events, and cardiovascular mortality in patients with PPCM. This parameter may be used to identify patients at high risk for adverse events and guiding selection for aggressive therapy in patients with PPCM.
| LI M ITATI O N S
The present study should be interpreted with certain limitations.
First, this was a retrospective single-center study. Although a relatively large series of patients with PPCM were investigated, the study population was limited in size due to the paucity of PPCM.
Prospectively designed studies on larger cohorts are necessary to validate our findings, to clarify the underlying mechanism, and to elucidate the prognostic utility of positive TaVR more accurately. Rather than a causal relation, we only demonstrated an association between upright T waves in lead aVR and adverse cardiovascular outcomes. Finally, we evaluated only initial presenting electrocardiograms, potential temporal changes in T wave were not examined in this study. It is probable that sequential measurements of T-wave amplitudes may have altered the results, effecting predictive value of TaVR either positively or negatively in PPCM patients.
| CON CLUS ION
Our findings revealed that positive T wave in lead aVR is significantly and independently associated with persistent LV systolic dysfunction, arrhythmic events as well as cardiac death in PPCM patients.
This unique ECG parameter in the often ignored lead gives additional
prognostic information beyond what is available with other known conventional risk factors and allows the recognition of patients at high risk of adverse CV outcomes. We recommend that a special attention should be paid to T-wave positivity in lead aVR whenever evaluating a woman with PPCM at initial evaluation given its high specificity and positive predictive value for predicting adverse cardiac events.
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